Literature DB >> 15720800

Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data.

Christian Pilarsky1, Michael Wenzig, Thomas Specht, Hans Detlev Saeger, Robert Grützmann.   

Abstract

Cancers originating from epithelial cells are the most common malignancies. No common expression profile of solid tumors compared to normal tissues has been described so far. Therefore we were interested if genes differentially expressed in the majority of carcinomas could be identified using bioinformatic methods. Complete data sets were downloaded for carcinomas of the prostate, breast, lung, ovary, colon, pancreas, stomach, bladder, liver, and kidney, and were subjected to an expression analysis using SAM. In each experiment, a gene was scored as differentially expressed if the q value was below 25%. Probe identifiers were unified by comparing the respective probe sequences to the Unigene build 155 using BlastN. To obtain differentially expressed genes within the set of analyzed carcinomas, the number of experiments in which differential expression was observed was counted. Differential expression was assigned to genes if they were differentially expressed in at least eight experiments of tumors from different origin. The identified candidate genes ADRM1, EBNA1BP2, FDPS, FOXM1, H2AFX, HDAC3, IRAK1, and YY1 were subjected to further validation. Using this comparative approach, 100 genes were identified as upregulated and 21 genes as downregulated in the carcinomas.

Entities:  

Mesh:

Year:  2004        PMID: 15720800      PMCID: PMC1531678          DOI: 10.1593/neo.04277

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  33 in total

1.  Identifying distinct classes of bladder carcinoma using microarrays.

Authors:  Lars Dyrskjøt; Thomas Thykjaer; Mogens Kruhøffer; Jens Ledet Jensen; Niels Marcussen; Stephen Hamilton-Dutoit; Hans Wolf; Torben F Orntoft
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

2.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Authors:  J B Welsh; P P Zarrinkar; L M Sapinoso; S G Kern; C A Behling; B J Monk; D J Lockhart; R A Burger; G M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.

Authors:  D A Notterman; U Alon; A J Sierk; A J Levine
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

4.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.

Authors:  J Luo; D J Duggan; Y Chen; J Sauvageot; C M Ewing; M L Bittner; J M Trent; W B Isaacs
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

5.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

Authors:  J M Boer; W K Huber; H Sültmann; F Wilmer; A von Heydebreck; S Haas; B Korn; B Gunawan; A Vente; L Füzesi; M Vingron; A Poustka
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

7.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.

Authors:  J B Welsh; L M Sapinoso; A I Su; S G Kern; J Wang-Rodriguez; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

8.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

9.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

10.  Molecular classification of human carcinomas by use of gene expression signatures.

Authors:  A I Su; J B Welsh; L M Sapinoso; S G Kern; P Dimitrov; H Lapp; P G Schultz; S M Powell; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

View more
  161 in total

1.  FoxM1 mediates resistance to herceptin and paclitaxel.

Authors:  Janai R Carr; Hyun Jung Park; Zebin Wang; Megan M Kiefer; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models.

Authors:  Tanya V Kalin; Vladimir Ustiyan; Vladimir V Kalinichenko
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

3.  Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Authors:  Vladimir Petrovic; Robert H Costa; Lester F Lau; Pradip Raychaudhuri; Angela L Tyner
Journal:  Cancer Biol Ther       Date:  2010-06-06       Impact factor: 4.742

4.  Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas.

Authors:  Charles Giardina; Masako Nakanishi; Awaad Khan; Anton Kuratnik; Wanli Xu; Bruce Brenner; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

5.  Type I interferon related genes are common genes on the early stage after vaccination by meta-analysis of microarray data.

Authors:  Junnan Zhang; Jie Shao; Xing Wu; Qunying Mao; Yiping Wang; Fan Gao; Wei Kong; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.

Authors:  Shahab Uddin; Maqbool Ahmed; Azhar Hussain; Jehad Abubaker; Nasser Al-Sanea; Alaa AbdulJabbar; Luai H Ashari; Samar Alhomoud; Fouad Al-Dayel; Zeenath Jehan; Prashant Bavi; Abdul K Siraj; Khawla S Al-Kuraya
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

7.  FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis.

Authors:  Nu Zhang; Ping Wei; Aihua Gong; Wen-Tai Chiu; Hsueh-Te Lee; Howard Colman; He Huang; Jianfei Xue; Mingguang Liu; Yong Wang; Raymond Sawaya; Keping Xie; W K Alfred Yung; René H Medema; Xi He; Suyun Huang
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

8.  A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.

Authors:  Darci J Trader; Scott Simanski; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2015-05-08       Impact factor: 15.419

9.  EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages.

Authors:  N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla
Journal:  Oncol Lett       Date:  2011-04-28       Impact factor: 2.967

10.  New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  Prostate       Date:  2010-06-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.